← Back to Clinical Trials
RecruitingNCT06309979

A Study to Assess Growth in Children With Idiopathic Short Stature

Trial Parameters

ConditionIdiopathic Short Stature
SponsorBioMarin Pharmaceutical
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment300
SexALL
Min Age2 Years
Max Age16 Years
Start Date2024-08-08
Completion2040-12-31

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.

Eligibility Criteria

Inclusion Criteria: 1. Participants must be \> 2 years old, and ≤ 14 years old (female) or ≤ 16 years old (males) at the time of signing the informed consent. 2. A height assessment corresponding to a height Z-score of ≤ -2.25 SDs in reference to the general population of the same age and sex, as calculated using the Centers for Disease Control and Prevention (CDC) growth chart (https://www.cdc.gov/growthcharts/zscore.htm). 3. Participants who have either never received hGH, or who are currently receiving hGH treatment. 4. Historic stimulation test result with serum or plasma GH level greater than 10 μg/L. 5. Parent(s) or guardian(s) are willing and able to provide written, signed informed consent. Exclusion Criteria: 1. Diagnosis of systemic disease or condition that may cause short stature, eg renal, neoplastic, pulmonary, cardiac, gastrointestinal, immunologic and metabolic disease. Children with such diagnoses can be considered for inclusion if their condition is well controlled, a

Related Trials